PATENT CLAIM ANALYSIS

Application Number: 15952424
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["435", "006110"]

Abstract:
The present disclosure relates to methods for the diagnosis and evaluation of neoplastic disorders, particularly non-small cell lung cancer. Assays are described in which patient test samples are analyzed for the presence of one or more specific EML4-ALK fusion genes associated with neoplastic disorders.

Claim (Index 33):
The method of  claim 30 , wherein the a labeled nucleic acid probe that hybridizes to the 3\u2032 insertion junction of an E17ins30;ins65A20 gene fusion comprises SEQ ID NO:28.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 91.0
- Lexical Diversity: 1.175
- Patent Class: 435.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13518232', '14928347', '14643181', '12466920', '11845498']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6949257025483923
- 35 USC 102 Novelty (BERT): 0.5923294768079804
- Combined Prediction Score: 0.684666079974351
- Mean Citation Score: 431.214824
- Max Citation Score: 550.77386
- Similarity Product: 440.4481884562146

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test